Boundless Bio, Inc.
About Boundless Bio, Inc.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$58.2M
- Total assets
- $157.1M
- Market cap
- $31.9M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $63.6M
- Operating income
- -$63.6M
- Income tax
- $0
- Net income
- -$58.2M
- EPS (basic)
- $-2.60
- EPS (diluted)
- $-2.60
Balance sheet
- Total assets
- $157.1M
- Current assets
- $109.6M
- Total liabilities
- $58.4M
- Current liabilities
- $12.5M
- Shareholders’ equity
- $98.7M
Cash flow
- Operating cash flow
- -$46.7M
- Investing cash flow
- $37.8M
- Financing cash flow
- $141.0K
- Net cash flow
- -$8.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $31.9M
- EPS (diluted)
- $-2.6
- Shares outstanding
- 22.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 28, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $58.2M.
- Trading 15% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Boundless Bio, Inc..
Write a review
News about Boundless Bio, Inc.
News & sentiment via Polygon.io
